Sun Pharmaceutical Industries Limited has announced the appointment of Ms. Satyavati Berera as an Independent Director. Subject to shareholder approval, she will serve a term of five consecutive years. With over 40 years of experience in leadership and consulting, Ms. Berera brings extensive expertise in finance, operations, and governance to the Board. Her addition is expected to further strengthen the company’s oversight, strategic decision-making, and overall corporate governance effectiveness.
Strengthening Board Governance
Sun Pharmaceutical Industries Limited has formally approved the appointment of Ms. Satyavati Berera to its Board of Directors. Serving as an Independent Director, her term is set for five consecutive years, effective from the date of shareholder approval. This appointment reflects the company’s commitment to maintaining a robust and diverse leadership team capable of navigating complex global business environments.
A Distinguished Career
Ms. Berera is a highly accomplished professional and the former Chief Operating Officer (COO) of PwC India. Her career spans more than 40 years, during which she held key leadership roles, including managing partner for the firm’s northern region and heading the consulting practice. A fellow member of the Institute of Chartered Accountants of India (ICAI), she possesses a deep understanding of finance, human capital, technology, and risk management.
Expertise and Strategic Value
Throughout her career, Ms. Berera has worked extensively across various industry sectors, focusing on Assurance, Consulting, and Governance Risk and Compliance (GRC). Her experience in designing control-strengthening solutions and process improvements for both domestic and multinational companies will be invaluable to Sun Pharma. Her expertise in the regulatory and compliance environment will serve to reinforce the board’s independence and strengthen its long-term strategic oversight.
Source: BSE
